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Background. Because humoral immunity is believed to play
a pivotal role in the pathogenesis of IgA nephropathy (IgAN),
a prospective placebo-controlled randomized study was started
in patients with IgAN using mycophenolate mofetil (MMF).
Methods. A total of 34 patients with IgAN were treated with
salt intake restriction, angiotensin-converting enzyme (ACE)
inhibition and MMF 2 g per day (N = 21) or placebo (N =
13). After 36 months of follow-up clinical, biochemical, and
radiologic data were analyzed using linear mixed models for
longitudinal data and Kaplan-Meier survival analysis.
Results. Therapy had to be stopped prematurely in five pa-
tients. Two patients (MMF group) evolved to end-stage renal
disease (ESRD). There was no difference between groups in
the percentage of patients with a decrease of 25% or more in
the inulin clearance or with a serum creatinine increase of 50%
or more over 3 years. There was also no significant difference
between groups in annualized rate of change of serum creati-
nine, computed by linear regression analysis. No significant dif-
ference was noted between groups for inulin clearance, serum
creatinine, proteinuria, blood pressure, or other parameters of
renal function. Hemoglobin and C-reactive protein were sig-
nificantly lower in the MMF group compared with the placebo
group. As a function of time, a significant decline in both groups
was noted of proteinuria, parenchymal thickness of the kidneys
and C3d.
Conclusion. In patients with IgAN at risk for progressive
disease, no beneficial effect of 3-year treatment with MMF 2 g
per day could be demonstrated on renal function/outcome or
proteinuria. However, larger randomized studies are needed to
confirm or reject these results.
IgA nephropathy (IgAN) is the most common
glomerulopathy in the world. The pathogenesis of the
Key words: IgA nephropathy, mycophenolate mofetil, renal function,
proteinuria, immunosuppression, immune disorder.
Received for publication June 27, 2003
and in revised form October 3, 2003
Accepted for publication December 1, 2003
C© 2004 by the International Society of Nephrology
disease is not fully understood [1]. While humoral immu-
nity is believed to play a pivotal role, characterized by the
predominant mesangial IgA1 deposition, also secondary
inflammatory processes may be important in the progres-
sion of renal injury [2, 3]. Immune-mediated glomeru-
lopathies like IgAN can be considered as resulting from
inappropriate activation of the immune response, fol-
lowed by an inflammatory reaction, and leading to pro-
gressive destruction of nephrons with ultimately renal
fibrosis. Renal failure develops in up to 30% of pa-
tients after 20 to 30 years [4–6]. Risk factors for un-
favorable prognosis have been defined, but to date no
curative treatment for IgAN is available [7–9]. Because
strategies aimed at stopping immune-mediated processes
have failed to cure IgAN until now, therapies have been
based largely at reducing hemodynamic stress by lower-
ing blood pressure and proteinuria via the angiotensin II
suppression, to retard progression of renal disease.
Recently, mycophenolate mofetil (MMF) was sug-
gested to be a promising therapeutic agent in the treat-
ment of IgAN [10, 11]. Mycophenolic acid (MPA),
released from MMF by tissue and systemic esterase activ-
ity, is a potent, reversible, and noncompetitive inhibitor of
inosine 5′-monophosphate dehydrogenase, a key enzyme
for de novo purine synthesis and for the glycosylation of
adhesion molecules in T and B lymphocytes [12–15]. As
such, MPA selectively inhibits the proliferation of T and
B lymphocytes, the production of antibodies, the genera-
tion of cytotoxic T cells and the recruitment of leukocytes
to sites of inflammation. Results from large-scale clinical
trials in renal transplantation demonstrated that MMF is
a highly effective immunosuppressive drug with an ac-
ceptable safety profile [16–18]. MMF has become one of
the standard immunosuppressive agents in many trans-
plant centers and has been successfully used in short-term
pilot studies to treat immune-mediated glomerulopathies
and systemic immune disorders [10, 11, 19–22]. There is,
however, also growing experimental evidence that the
anti-inflammatory properties of MMF may, by attenu-
ating glomerular and interstitial injury, be beneficial in
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the treatment of progressive nephropathies [23–25]. At
present, no unequivocal clinical data supporting this hy-
pothesis are available.
The effect of MMF in addition to angiotensin-
converting enzyme (ACE) inhibition—the reference
renoprotective treatment—combined with other strate-
gies (rigorous blood pressure control, sodium restriction,
nondihydropyridine calcium blockade) that interfere
with progressive proteinuric nephropathies has never
been studied in humans. The aim of this single-center,
prospective, placebo-controlled randomized study was to
evaluate the effect of MMF 2 g per day versus placebo,
in addition to standard renoprotective treatment, during
a 3-year period on the progression of renal disease in pa-
tients with IgAN with prognostic unfavorable features,
but judged not to be treated with corticosteroids and/or
cytotoxic agents.
METHODS
Study design
The study was a single-center, prospective, placebo-
controlled, randomized comparison of treatment with
MMF 2 g/day versus placebo for 3 years. The diagnosis of
IgAN was based on histologic assessment of renal biopsy
tissue stained with hematoxylin and eosin, periodic acid-
Schiff (PAS) and methenamine silver for light microscopy
and staining with C1q, C3, IgG, IgA, and IgM for im-
munohistology, showing pre- or codominant mesangial
deposition of IgA. The study protocol was approved by
the Ethics Committee of the University of Leuven and
all patients gave written informed consent.
Patient selection
The inclusion criteria consisted of (1) age 18 years and
older, (2) written informed consent, and (3) renal biopsy
proven IgAN within 5 years, in conjunction with a de-
creased renal function at diagnosis [as defined by an in-
ulin clearance >20 but <70 mL/min/1.73 m2 body surface
area (BSA)] and/or proteinuria >1 g/day/1.73 m2 BSA
and/or arterial hypertension (≥140 mm Hg systolic or
≥90 mm Hg diastolic or currently being treated for hyper-
tension) and/or histologic unfavorable criteria (grades II
to IV defined by Churg and Sobin [26] and/or glomerular
capillary wall IgA deposits).
Exclusion criteria were rapidly progressive IgAN
(IgAN with rapid decline in renal function character-
ized histologically by necrotizing capillaritis and crescent
formation) necessitating the use of other immunosup-
pressive drugs, other renal diseases and systemic diseases
[systemic lupus erythematosus (SLE), Goodpasture
syndrome, vasculitis], the intake of other immuno-
suppressive drugs or any study drug during the last
6 months, pregnancy, lactation or women with child-
bearing potential using no effective contraceptives,
malignancy, active central nervous/hepatic/metabolic/
cardiovascular/gastrointestinal diseases, psychiatric an-
tecedents, ongoing or latent infections, leukopenia
(<3000/mm3) or thrombocytopenia (<75.000/mm3) or a
contraindication for the use of ACE inhibitors.
The screening phase consisted of a complete medi-
cal history, clinical examination, electrocardiogram, ul-
trasound of the abdomen, blood [serum creatinine,
urea, sodium, potassium, chloride, bicarbonate, calcium,
phosphate, protein content and electrophoresis, fasting
glucose, bilirubin, aspartate aminotransferase (SGOT),
alanine aminotransferase (SGPT), alkaline phosphatase,
lactatedehydrogenase, gamma-glutamyltransferase, uric
acid, complet and formula, partial thromboplastin time
(PTT), IgG/A/M, C-reactive protein, Rheuma Factor,
complement (CH50, C3, C3d, and C4), antinuclear factor,
antineutrophilic cytoplasmic antibodies (ANCAs), circu-
lating immune complexes, and hepatitis B and C serology]
and urine (urine sediment, creatinine clearance, 24-hour
proteinuria, and salt excretion) analysis and evaluation
of the renal biopsy.
Patient treatment and monitoring
Eligible patients were randomized (2:1; MMF:placebo)
and treated with restriction of salt intake (aimed at
< 5 g NaCl/day), ACE inhibitors (aimed blood pressure
125/75 mm Hg) and either MMF (Cellcept) (Hoffmann-
LaRoche, Basel, Switzerland) 1 g twice a day or placebo
(identical lactose-containing capsules) twice a day. Clin-
ical examination, blood (routine biochemistry, serum
IgA/G/M, and serum complement) and urine (urine sed-
iment, measured creatinine clearance, 24-hour protein-
uria, and salt excretion) analysis was performed at 1, 2,
and 3 months, and every 3 months thereafter; MPA pre-
dose level, ultrasound of the kidneys, and inulin clearance
was performed every 12 months after randomization.
The following guidelines with regard to the MMF ther-
apy were followed. At every visit, the patients were clin-
ically examined and judged on tolerance and adverse
effects (especially infections). In infectious complica-
tions, MMF was to be discontinued until resolution
of symptoms. In case of gastrointestinal intolerance of
MMF, the dose of MMF was to be reduced (from 1 g twice
a day to 0.5 g twice a day; and if persistent from 0.5 g twice
a day to 0.25 g twice a day). If dose reduction was not suffi-
cient to resolve the symptoms, MMF was to be stopped. In
case of leukopenia <3000 white blood cells/mm3 and/or
thrombocytopenia <75,000/mm3, the dose of MMF was
to be reduced to 0.5 g twice a day. In case of leukope-
nia <2000 white blood cells/mm3 and/or thrombocytope-
nia <50,000/mm3, MMF was to be discontinued for at
least 2 weeks. After disappearance of the gastrointestinal
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symptoms or restoration of the cell counts, MMF could
be reintroduced starting at a dose of 0.5 g twice a day.
As far as blood pressure was concerned, enalapril
(Renitec; Merck, Sharp & Dohme, Whitehouse Sta-
tion, NJ, USA) was used as first line treatment and doses
were increased until blood pressure was <130/80 mm Hg.
If supplementary antihypertensive drugs were needed,
titration was done using the nondihydropyridine cal-
cium antagonist verapamil (Lodixal) (Knoll AG,
Ludwigshafen, Germany), followed by other. Restriction
of salt intake was instructed and monitored using 24-hour
NaCl excretion.
Study end points
The primary end point of the study was the loss of
renal function, defined as a decrease of 25% or more
in the inulin clearance during the 3-year treatment pe-
riod. Secondary end points were the cumulative percent-
age of patients that were free of death, development
of end-stage renal disease (ESRD) (defined as chronic
repetitive dialysis or renal transplantation) or discontin-
uation of therapy due to adverse events or noncompli-
ance, the cumulative percentage of patients that were
free of death, development of ESRD, and the cumula-
tive percentage of patients whose serum creatinine in-
creased by 50% or more over 3 years. Other variables
monitored included changes in blood pressure, the es-
timated annualized within-patient slope in serum creati-
nine, serum urea, albumin, C-reactive protein, peripheral
blood counts, immunoglobulins and complement fac-
tors, 24-hour creatinine clearance, 24-hour proteinuria,
24-hour renal sodium excretion, the number of red blood
cells per high power field and the percentage of dysmor-
phic red blood cells in the urine, bipolar diameter (mean
of left and right) and parenchymal thickness of the kid-
neys (mean of left and right upper pole, interpolar region
and lower pole), and MPA predose levels. The treatment
code was broken for patients reaching ESRD, death, or
premature stop of the study due to serious adverse events
or patient’s decisions.
Statistical analyses
Continuous variables were summarized as means and
SD or SEM. Univariate baseline comparisons between
the two groups were done using the Wilcoxon rank sum
test (SAS, PROC NPAR1WAY) or chi-square test (SAS,
PROC FREQ) [27]. The cumulative percentage of pa-
tients with a decrease of 25% or more in the inulin clear-
ance, the cumulative percentage of patients that were
free of death, development of ESRD (or discontinua-
tion of therapy) and the cumulative percentage of pa-
tients whose serum creatinine increased by 50% or more
in both groups was calculated by Kaplan-Meier survival
analysis (SAS, PROC LIFETEST) [27]. The annualized
slope in serum creatinine was calculated using linear re-
gression analysis in each patient; the Wilcoxon rank sum
test was then used to compare the distributions of the
slopes in both groups. The clinical, biochemical, and ra-
diologic variables monitored at regular intervals over a
period of 36 months were compared in the two groups
using linear mixed models for longitudinal data (SAS,
PROC MIXED) [27, 28].
RESULTS
Between October 1997 and December 1999, 49 patients
with IgAN were screened for this study. Thirty-four met
the criteria for eligibility and were willing to enter the
study. Twenty-one were assigned to receive MMF, and 13
to receive placebo. The baseline clinical and laboratory
characteristics of the patients in both groups were similar.
At the time of randomisation, the age was 39 ± 11 years
in the MMF group versus 43 ± 15 years in the placebo
group (P = 0.37). There were no differences in gender
(76% versus 62% male; P = 0.29), race (90% versus 92%
Caucasian; P = 0.45), number of hypertensive patients
(86% versus 85%; P = 0.73), or time elapsed from renal
biopsy to randomization (3.4 ± 1.7 years versus 3.7 ±
2.1 years; P = 0.19). And there were also no significant
differences in baseline data of systolic (P = 0.40) and
diastolic (P = 0.94) blood pressure, renal function [inulin
clearance (P = 0.57), serum creatinine (P = 0.65), 24-hour
proteinuria (P = 0.17)] or 24-hour urinary NaCl excretion
(P = 0.25).
Outcome
In the follow-up of the 34 patients who entered the trial,
one patient in the placebo group died due to metastasized
rectal carcinoma, and two patients in the MMF group
evolved to ESRD. Therapy was stopped prematurely in
another four patients due to adverse events (one subject
in each group) or emigration (MMF group, two subjects).
Nine patients (seven in the MMF group and two in
the placebo group) reached the primary end point of the
study, a decrease of 25% or more in the inulin clearance at
36 months. The respective Kaplan-Meier estimates were
33% and 15% (log-rank P =0.3357; Wilcoxon P =0.3650)
(Fig. 1A). Survival free of ESRD, adverse events lead-
ing to discontinuation of treatment or refusal to continue
therapy was also similar in both groups (76% versus 85%)
(log-rank P = 0.6555; Wilcoxon P = 0.7420) (Fig. 1B).
Also survival free of ESRD was similar in both groups
(89% versus 92%) (log-rank P = 0.8179; Wilcoxon P =
0.8388). There was also no difference in the cumulative
percentage of patients whose serum creatinine increased
by 50% or more in both groups (14% versus 0%) (log-
rank P = 0.1560; Wilcoxon P = 0.1605) (Fig. 1C).
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Fig. 1. Cumulative percentage of patients with IgA nephropathy (IgAN) treated with mycophenolate (MMF) or placebo (PLA). (A) Patients
whose inulin clearance decreased by 25% or more. (B) Patients who were free of death, development of end-stage renal disease (ESRD), or
premature discontinuation of therapy. (C) Patients whose serum creatinine increased by 50% or more during the 3-year treatment period.
Changes in renal function and morphology and
management of hypertension
Renal function was maintained equally in both pa-
tient groups, as indicated by evolution of inulin clearance,
serum creatinine, and by the median annual changes in
serum creatinine concentration (Fig. 2) (Table 1). The an-
nualized median change in serum creatinine was 0.11 mg/
dL per year in the MMF group and 0.05 mg/dL per year
in the placebo group (P = 0.5007).
A small but significant decline in proteinuria was noted
in both groups as a function of time; differences between
groups were absent. There was also no difference in the
cumulative percentage of patients whose proteinuria de-
creased or increased by 50% or more or in the percent-
age of patients with proteinuria more than 1 g or 3 g per
day over time. No differences were noted within or be-
tween groups in number of urinary red blood cells per
high power field or in the percentage of dysmorphic uri-
nary red blood cells.
Although the bipolar diameter of the kidneys remained
unchanged over the treatment period of 3 years, a signif-
icant decline in parenchymal thickness could be noted in
both groups as a function of time; the differences between
groups, however, were not significant (Fig. 3) (Table 1).
Both systolic and diastolic blood pressures were simi-
lar in both groups and did not change significantly during
the treatment period (Table 1). Nine patients (27%), six in
the MMF group and three in the placebo group, were al-
ready on enalapril before enrollment in the study. All but
one patient were treated with enalapril and also received
other antihypertensive drugs, including calcium antago-
nists (verapamil) [14 (eight MMF/six placebo)], adrener-
gic antagonists (eight), centrally acting alpha2-adrenergic
agonists (one), and diuretic agents (six). Two patients
(one in both groups) developed symptomatic hypoten-
sion to enalapril, for which enalapril had to be stopped;
no other adverse effects to antihypertensive treatment
was noted. The dose of enalapril was twice as high in the
MMF group (19 ± 12 mg/day) compared with the placebo
group (11 ± 7 mg/day) (P = 0.0484). Renal sodium chlo-
ride excretion initially dropped in both groups due to
dietary restrictions, but then again rose from month 6 on
in both groups.
Changes in biochemistry
A small but significant increase over 3 years was
noted in hemoglobin (or hematocrit/red cell count) in the
placebo group that was absent in the MMF group. There
was also a small but consistent difference between groups
in C-reactive protein. In both groups, complement factor
C3 slightly but significantly increased. This was associated
with a significant decrease in C3d. No other significant
differences in biochemistry were present.
1846 Maes et al: MMF in IgA nephropathy
0
20
40
60
80
100
120
In
ul
in
 c
le
ar
an
ce
, m
l/m
in
/1
.7
3m
2
MMF PLA
0 12 24 36
Time, months
0 12 24 36
Time, months
A
MMF PLA
B
0
1
2
3
Se
ru
m
 c
re
at
in
in
e,
 m
g/
dL
–1
0
1
2
Ch
an
ge
 in
 s
er
um
 c
re
at
in
in
e,
m
g/
dL
/y
r
MMF PLA
C
Fig. 2. Inulin clearance (A) (mean ± SEM), serum creatinine (B) (mean ± SEM) and annualized rate of change in serum creatinine (C) in patients
with IgA nephropathy (IgAN) treated with mycophenolate mofetil (MMF) or placebo (PLA).
Table 1. Renal function and morphology, and blood pressure: Comparison of results from baseline to 36 months of therapy in patients with IgA
nephropathy (IgAN) treated with mycophenolate mofetil (MMF) or placebo during the 3-year treatment period (mean ± SEM)
MMF Placebo
Linear mixed model P value
Month 0 Month 36 Month 0 Month 36 Treatment effect Time effect
Inulin clearance mL/min/1.73 m2 73 ± 5 60 ± 7 69 ± 7 67 ± 7 0.33 0.95
Serum creatinine mg/dL 1.46 ± 0.08 1.72 ± 0.35 1,39 ± 0,10 1.48 ± 0.16 0.12 0.97
Serum urea mg/dL 47 ± 4 53 ± 11 47 ± 5 48 ± 6 0.23 0.92
Bipolar diameter cm 10.5 ± 0.9 10.7 ± 0.8 10.5 ± 1.1 10.2 ± 1.1 0.20 0.94
Parenchymal thickness mm 15.8 ± 0.7 14.6 ± 0.5 16.7 ± 0.6 13.9 ± 0.6 0.92 0.0013
Proteinuria g/day 1.9 ± 0.3 1.6 ± 0.6 1.3 ± 0.4 1.0 ± 0.6 0.97 0.0001
Systolic blood pressure mm Hg 122 ± 4 125 ± 3 134 ± 8 124 ± 8 0.12 0.72
Diastolic blood pressure mm Hg 80 ± 3 74 ± 2 80 ± 3 71 ± 5 0.27 0.75
Renal sodium excretion g/day 8.6 ± 0.8 7.8 ± 0.7 6.7 ± 0.9 7.6 ± 1.5 0.95 0.0089
Number of urinary red blood cells/high power field 149 ± 51 51 ± 25 111 ± 33 29 ± 18 0.15 0.55
Dysmorphic urinary red blood cells % 64 ± 6 66 ± 9 73 ± 6 40 ± 8 0.28 0.82
Compliance with treatment and adverse reactions
As a measure of compliance, MPA predose levels were
dosed every year in the MMF-treated group. Nonde-
tectable predose levels were absent in all patients at any
time. As shown in Figure 4, a mean predose level of
3.5 mg/L was measured after 1 year of treatment, fol-
lowed by a slight nonsignificant increase over time (P =
0.7489). Reactivation of pulmonary tuberculosis in a pa-
tient of Indian origin 4 months after study entry required
the discontinuation of MMF treatment; a good response
to antimycobacterial therapy (isoniazid, rifampicin, and
ethambutol) was obtained. Two patients developed gas-
trointestinal complaints (nausea and epigastric pain) for
which the dose of MMF was reduced; a transient dose
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Table 2. Biochemistry: comparison of results from baseline to 36 months of therapy in patients with IgA nephropathy (IgAN) treated with
mycophenolate mofetil (MMF) or placebo during the 3-year treatment period (mean ± SEM)
MMF Placebo
Linear mixed model P value
Month 0 Month 36 Month 0 Month 36 Treatment effect Time effect
Hematocrit % 43 ± 1 43 ± 2 39 ± 1 42 ± 1 0.0069 0.98
Hemoglobin g/dL 14.4 ± 0.3 14.1 ± 0.6 13.0 ± 0.5 13.9 ± 0.6 0.0056 0.99
Red blood cell count 1012/L 4.81 ± 0.12 4.88 ± 0.21 4.23 ± 0.17 4.53 ± 0.20 <0.0001 0.99
White blood cell count 109/L 7.3 ± 0.6 6.7 ± 0.5 6.4 ± 0.4 6.7 ± 0.5 0.72 0.94
Lymphocyte count % 28 ± 2 25 ± 3 27 ± 2 26 ± 2 0.68 0.99
Platelet count 109/L 263 ± 16 265 ± 25 279 ± 9 254 ± 17 0.07 0.17
C-reactive protein mg/L 4.1 ± 0.7 3.5 ± 0.5 4.8 ± 0.7 5.1 ± 0.7 0.0001 0.79
IgA g/L 3.2 ± 0.2 2.6 ± 0.3 3.0 ± 0.2 2.8 ± 0.3 0.41 0.89
IgG g/L 9.6 ± 0.6 9.6 ± 1.0 9.8 ± 0.8 9.3 ± 0.7 0.52 0.99
IgM g/L 1.1 ± 0.1 0.7 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.42 0.98
Albumin g/L 40.5 ± 0.9 38.7 ± 1.0 39.5 ± 1.3 39.2 ± 1.0 0.85 0.30
C3 g/L 1.05 ± 0.04 1.06 ± 0.09 1.07 ± 0.04 1.15 ± 0.12 0.48 0.01
C3d % 2.4 ± 0.2 1.7 ± 0.2 2.1 ± 0.3 1.4 ± 0.1 0.23 0.0004
C4 g/L 0.25 ± 0.02 0.23 ± 0.03 0.25 ± 0.02 0.25 ± 0.04 0.96 0.52
CH50 U/mL 514 ± 25 526 ± 22 508 ± 36 517 ± 35 0.86 0.56
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Fig. 3. Bipolar diameter (mean of left and right kidney) (A) and parenchymal thickness (mean of left and right upper pole, interpolar region and
lower pole) (B) (mean ± SEM) in patients with IgA nephropathy (IgAN) treated with mycophenolate mofetil (MMF) or placebo (PLA).
reduction was required in one patient with a temporary
leukopenia. The mean dose of MMF was 1.85 ± 0.45 g/
day.
In the placebo group, one patient became pregnant
6 months after inclusion in the study after stopping oral
contraceptives; the pregnancy evolved uneventfully. An-
other female developed rectal carcinoma 12 months af-
ter study entry and died of disseminated disease 2 months
later. No adverse effects were noted in the placebo group.
DISCUSSION
This prospective, placebo-controlled randomized study
failed to show an additive effect of MMF 2 g/day ver-
sus placebo added to salt intake restriction and ACE
inhibitors during a 3-year period on the progression of
renal disease in patients with IgAN with prognostic un-
favorable features. This is in contrast with the benefi-
cial effects of MMF reported in other immune-mediated
nephropathies and anecdotic reports in IgAN (10, 11, 19–
22). Several factors have to be taken into account.
First, the number of patients included was small be-
cause of the single-center design; on the other hand, it
allowed to evaluate some markers of renal disease and
therapy accurately (inulin clearance, immunology, ultra-
sound of the kidneys by one radiologist, and dosing of
MPA). Moreover, in order to maximize the number of
patients treated with MMF, a 2:1 randomization has been
performed. However, the conclusions have to interpreted
with caution since the study is statistically not powered to
unequivocally prove differences or equivalence between
the two groups. Therefore, large multicenter trials are
warranted in the future to confirm or reject these results.
Second, patient selection may have influenced the out-
come of the study. Patients judged to be treated with
corticosteroids and/or cytotoxic agents [(1) rapidly pro-
gressive IgAN and (2) patients with mild histopatho-
logic changes, proteinuria >3 g/day and preserved renal
function (creatinine clearance >70 mL/min)] [6] were
1848 Maes et al: MMF in IgA nephropathy
0
2
4
6
M
PA
 
pr
e-
do
se
 le
ve
l, 
m
g/
L
0 12 24 36
Time, months
Fig. 4. Mycophenolic acid (MPA) predose level (mean ± SEM) in
patients with IgA nephropathy (IgAN) treated with mycophenolate
mofetil (MMF).
excluded; whether an additional beneficial effect of MMF
in these groups can be obtained is not addressed in this
study. Because experimental data showed that effective
renal protection by MMF in some nephropathies oc-
curred if it was instituted early in the course of the disease
[29–31], only patients with IgAN without severe renal
insufficiency were studied. Nevertheless, risk factors for
progression (hypertension, proteinuria, decreased renal
function, and histologic criteria) had to be present. As
a result, the annualized rate of change in serum creati-
nine was comparable with other studies in IgAN with
moderate renal disease and slightly lower compared with
some studies in severe IgAN [32, 33]. In 27% of patients,
enalapril was already started before enrollment in the
study, albeit with an equal distribution in the two groups.
And no differences in evolution of renal function or pro-
teinuria have been observed between patients with and
without ACE inhibition at the time of enrollment. The
dose of enalapril was twice as high in the MMF-group
compared with the placebo group, as a result of dosing ac-
cording to blood pressure control and tolerance. Because
no influence of MMF on blood pressure has ever been re-
ported in humans, this might indirectly indicate a more
severe disease or more rapid progression in patients on
MMF treatment. However, no markers at baseline or dur-
ing follow-up pointed at significant differences in severity
or progression of IgAN (renal function or morphometry,
proteinuria, blood pressure, or salt intake).
In this subset of patients with IgAN (that probably
represents the major part of patients with progressive
IgAN) administration of MMF 2 g/day during a 3-year
period of time offered no benefit over the standard ther-
apy of salt restriction, angiotensin II suppression and
frequent follow-up (compliance) as far as (renal) out-
come or proteinuria is concerned. None of the immuno-
logic parameters measured suggested a positive influence
of MMF on inappropriate activation of the immune re-
sponse (immunoglobulin A/G/M, complement factors).
On the other hand, patients in the MMF group dis-
played a significantly lower C-reactive protein, compati-
ble with the anti-inflammatory properties of MMF. While
these anti-inflammatory properties of MMF exerted ef-
fective renal protection (agonistic with ACE inhibition)
in the early course of both immune and nonimmune
nephropathies in experimental models [23, 29–31], this
resulted not in clinically measurable benefits in humans
with IgAN on standard therapy. The small but significant
decline of proteinuria, parenchymal thickness, and C3d
with associated increase of total C3 in both groups are
suggestive for anti-inflammatory actions of the standard
therapy based on the consideration to ameliorate hemo-
dynamic stress or immune injury.
Although the safety profile of MMF is favorable and
only minor adverse effects were noted in this study, the
risks of prolonged immunosuppression by MMF [lym-
phoma, cytomegalovirus (CMV) disease] without clini-
cal benefits made us stop the study after 3 years. Whether
the decreasing hemoglobin level is due to the administra-
tion of MMF or the higher doses of ACE inhibitor in this
group is not known. And, whether higher doses of MMF
are able to slow progressive disease in this subset of pa-
tients with IgAN is not answered by this study. However,
the measured MPA predose levels were within the ranges
accepted as safe and effective to prevent allograft rejec-
tion, albeit in dual or triple immunotherapy. The slight
but not significant increase of MPA predose levels are in
agreement with the observations in organ transplantation
of a gradual increase of exposure to MPA with time [34].
Because of the interindividual variability of exposure, in-
creasing the dose to 3 g MMF per day would probably give
rise to more (serious) adverse effects. Therefore, future
studies with MMF in immune disorders should use MPA
levels to monitor adequate individual exposure rather
than fixed doses.
CONCLUSION
In patients with IgAN with moderate risk for pro-
gressive disease, no beneficial effect of three years treat-
ment with MMF 2 g/day could be demonstrated on renal
outcome/function or proteinuria. However, larger mul-
ticenter studies are warranted to confirm or reject these
findings.
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